• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolones and derivatives
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients

Palonosetron Hydrochloride (CAS No: 135729-62-3) - A Comprehensive Overview

Palonosetron Hydrochloride, with the chemical identifier CAS No: 135729-62-3, is a well-established pharmaceutical compound that has garnered significant attention in the field of chemobiology and medicinal chemistry. This compound belongs to the class of selective serotonin 5-HT3 receptor antagonists, which are widely utilized for their potent anti-emetic properties. The introduction of Palonosetron Hydrochloride into clinical practice has marked a significant advancement in the management of chemotherapy-induced nausea and vomiting (CINV), offering patients a more effective and prolonged duration of action compared to earlier generations of anti-emetics.

The mechanism of action of Palonosetron Hydrochloride revolves around its high-affinity binding to the 5-HT3 receptors located in the gastrointestinal tract and the central nervous system. By blocking the action of serotonin, a neurotransmitter that is released during chemotherapy, this compound effectively prevents the activation of these receptors, thereby mitigating the nausea and vomiting associated with cancer treatment. The unique pharmacological profile of Palonosetron Hydrochloride is characterized by its prolonged receptor occupancy, which translates to a more sustained anti-emetic effect, making it particularly valuable in patients undergoing highly emetic chemotherapy regimens.

Recent advancements in the understanding of the pharmacodynamics and pharmacokinetics of Palonosetron Hydrochloride have further highlighted its clinical significance. Studies have demonstrated that the compound exhibits a longer half-life compared to other 5-HT3 receptor antagonists, such as ondansetron and granisetron. This extended duration of action is attributed to the higher lipophilicity and slower dissociation rate of Palonosetron Hydrochloride from its binding sites. These properties not only enhance patient convenience by reducing the frequency of dosing but also improve overall therapeutic efficacy by maintaining consistent levels of receptor blockade.

The clinical applications of Palonosetron Hydrochloride extend beyond the standard management of CINV. Emerging research suggests that this compound may also have potential benefits in other areas, including the treatment of post-operative nausea and vomiting (PONV) and even certain neurological disorders characterized by serotonin receptor overactivity. For instance, preliminary studies have explored the use of Palonosetron Hydrochloride in patients with irritable bowel syndrome (IBS), where serotonin dysregulation plays a significant role. While further research is needed to fully elucidate these potential applications, they underscore the broad therapeutic spectrum that this compound may possess.

The synthesis and chemical structure of Palonosetron Hydrochloride (CAS No: 135729-62-3) are also subjects of considerable interest in medicinal chemistry. The compound features a complex molecular framework that includes a piperazine ring and a pyridine moiety, which contribute to its high selectivity for 5-HT3 receptors. The hydrochloride salt form enhances its solubility and bioavailability, facilitating easier administration via intravenous or oral routes. The synthetic pathways employed in the production of Palonosetron Hydrochloride have been optimized to ensure high yield and purity, meeting stringent pharmaceutical standards required for clinical use.

In terms of safety and tolerability, Palonosetron Hydrochloride has demonstrated an favorable adverse effect profile in multiple clinical trials. Common side effects include headache, constipation, and diarrhea, which are generally mild to moderate in severity. These effects are often transient and do not typically require discontinuation of therapy. However, as with any pharmaceutical agent, careful consideration should be given to individual patient factors such as renal impairment or concurrent medication use, which might influence dosing adjustments or increase the risk of adverse events.

The regulatory landscape for Palonosetron Hydrochloride, under its generic name or branded formulations like Aloxi? (a commonly known brand), reflects its established efficacy and safety profile. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved this compound for various indications based on robust clinical evidence supporting its benefits over existing anti-emetic agents. Ongoing post-marketing surveillance continues to monitor for any rare or long-term adverse effects, ensuring that patient safety remains paramount.

The future direction of research involving Palonosetron Hydrochloride (CAS No: 135729-62-3) is likely to focus on expanding its therapeutic applications and optimizing its use in combination with other treatments. Investigational studies are exploring its potential role in managing nausea associated with radiotherapy and certain surgical procedures where emesis is a common complication. Additionally, efforts are being made to develop novel formulations that could enhance drug delivery systems, such as oral suspensions or extended-release tablets, which might offer even greater convenience for patients.

In conclusion, Palonosetron Hydrochloride, identified by its CAS number 135729-62-3, represents a cornerstone in modern anti-emetic therapy. Its unique pharmacological properties provide clinicians with an effective tool for preventing chemotherapy-induced nausea and vomiting, while ongoing research continues to uncover additional potential applications across various medical disciplines. As our understanding of serotonin receptor biology advances, it is likely that compounds like Palonosetron will continue to play a pivotal role in enhancing patient care and improving quality-of-life outcomes for those undergoing potentially emetic treatments.

• 135729-78-1((S)-N-(1-Azabicyclo2.2.2oct-3-yl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamide)
• 135729-75-8((R,R)-Palonosetron Hydrochloride)
• 520-03-6(2-Phenylisoindole-1,3-dione)
• 135729-56-5(Palonosetron)
• 50-35-1(Thalidomide)
• 550-44-7(2-Methylisoindole-1,3-dione)
• 149653-99-6((5R)-3-(3R)-1-azabicyclo2.2.2octan-3-yl-3-azatricyclo7.3.1.0,5,13trideca-1(13),9,11-trien-2-one)
• 135729-61-2(Palonosetron)
• 776-75-0(1-Benzoylpiperidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)